Operating CF
$11.98B
Capex
−$2.50B
Free Cash Flow
$9.48B
FCF Margin
+79.1%
Cash flow waterfall for Pfizer (PFE) — TTM through Q1 2026
Free cash flow: $9.48B
Cash flow breakdown for Pfizer (PFE) — TTM through Q1 2026
| Line item | Amount | Running total |
|---|---|---|
| Operating Cash Flow | $11.98B | $11.98B |
| Capital Expenditure | −$2.50B | $9.48B |
| Free Cash Flow | $9.48B | $9.48B |
| Acquisitions | −$13.24B | −$3.75B |
| Other Investing | $11.90B | $8.14B |
| Dividends Paid | −$9.78B | −$1.63B |
| Net Debt Change | $2.23B | $599.00M |
| Other Financing & FX | −$324.00M | $275.00M |
| Net Cash Increase | $275.00M | $275.00M |
- Operating Cash Flow$11.98B
- Capital Expenditure−$2.50B
- Free Cash Flow$9.48B
- Acquisitions−$13.24B
- Other Investing$11.90B
- Dividends Paid−$9.78B
- Net Debt Change$2.23B
- Other Financing & FX−$324.00M
- Net Cash Increase$275.00M
Want to see what drove the FCF change?Free Cash Flow Bridge
Frequently asked questions
Data & methodology
Pfizer (PFE) Key Financials
Charts, filings, and peer comparison for every metric
Income Statement
Balance Sheet
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation
Overview
Income Statement